184 results about "Vascular problem" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention discloses a post-stroke depression risk prediction system based on cerebral small vascular diseases and inflammatory markers, and relates to the technical field of computer-aided engineering, the post-stroke depression risk prediction system comprises: a data acquisition module acquires CSVD image data, serum inflammatory markers and clinical baseline information; the data preprocessing module processes image denoising registration, fills up marker missing values and encodes clinical information; the CSVD feature extraction module extracts image omics features and quantifies severity; the inflammation marker module calculates statistical characteristics and inflammation intensity; the multi-dimensional fusion module integrates features and eliminates redundancy; the risk prediction module is trained by using an improved attention CNN-LSTM model; the result output module visualizes risk and intervention suggestions; the model dynamic optimization module updates parameters by incremental learning. According to the method, multi-source key data are integrated, the prediction accuracy and generalization ability are improved, clinical interpretation and dynamic adaptability are achieved, early recognition of post-stroke depression is assisted, and patient prognosis is improved.

The invention relates to the technical field of blood vessel structure recognition, and discloses an automatic recognition method and system for an OCT image blood vessel structure, and the method comprises the steps: 1, blood vessel layer boundary feature extraction: extracting blood vessel layer boundary features, including geometric features and physical features, from an OCT image based on multi-scale Hessian matrix response, and forming a feature response graph; step 2, three-layer topological structure identification: constructing a topological relation of a blood vessel structure according to the feature response diagram, and extracting a nested annular structure; identifying and outputting a three-layer initial boundary coordinate point set and a structure score of an inner membrane, a middle membrane and an outer membrane of a blood vessel; and step 3, optimizing a blood vessel structure: accurately optimizing the initial boundary coordinate point set, detecting special cells in an optimized region, and generating a result report. According to the method, full-automatic recognition of the OCT blood vessel structure is achieved, reliability, accuracy and interpretability of a recognition result are ensured, and standardization and unification of vascular disease diagnosis are ensured.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I):and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses a method for adjusting administration dosage according to adverse reaction risk based on a joint model, and is applied to the field of intelligent medical treatment. In the prior art, the relationship between the sirolimus steady-state valley concentration and the specific adverse reaction cannot be quantified, so that the defect of lack of accurate guidance for clinical medication is caused. Through systematic research, the method determines the individual target valley concentration range through a BKMR model for the first time, obtains individual pharmacokinetic parameters of a patient through a group pharmacokinetic model, and finally determines the medication time and the medication dosage of the patient through Bayesian negative feedback simulation, and the medication time and the medication dosage are used for adjusting a medication scheme. According to the invention, prospective risk prediction of adverse reactions of sirolimus is realized, the treatment safety of children with vascular diseases is remarkably improved, and long-term prognosis of patients is improved.

The invention is applied to the technical field of health-care products, and discloses a sea-buckthorn soft capsule, which comprises a capsule shell and a content, the capsule shell is composed of gelatin, water, glycerin and an auxiliary material, the auxiliary material is a preservative or a plasticizer, the content is composed of one of seabuckthorn seed oil or fruit oil, seabuckthorn powder and an auxiliary material, the auxiliary material is one of a suspending aid and an antioxidant or a mixture of the suspending aid and the antioxidant, the seabuckthorn powder is rich in flavone, and the auxiliary material is a mixture of the suspending aid and the antioxidant. The soft capsule has the effects of lowering lipid, softening blood vessels and preventing vascular diseases. According to the hippophae rhamnoides soft capsule, a product capsule shell is prepared from gelatin, water and glycerin according to a specific proportion, it can be guaranteed that the capsule shell has proper hardness and elasticity and is convenient to process and store, hippophae rhamnoides seed (fruit) oil and hippophae rhamnoides powder in the content are matched according to a reasonable proportion, the hippophae rhamnoides powder is rich in flavone, and the hippophae rhamnoides powder and the hippophae rhamnoides seed (fruit) oil act the effects of lowering lipid, softening blood vessels and preventing vascular diseases can be better exerted.

The application discloses a kind of nnUNet zebra fish juvenile whole brain vascular system segmentation methods based on autonomous data set training, it is related to high-resolution imaging technology, image processing and medical image segmentation field, the method makes full use of zebra fish live transparency and fluorescent label advantage, obtains high-resolution whole brain three-dimensional vascular image data, and constructs high-quality segmentation truth value database by semi-automatic segmentation and artificial correction, training is carried out using nnU-Net deep learning model, realize the three-dimensional automatic segmentation of zebra fish brain vascular system signal.The application method significantly improves the degree of automation and precision of image segmentation, effectively solves the problems of low efficiency, high artificial dependence and poor repeatability of traditional brain vascular segmentation.The method is suitable for large-scale high-throughput data processing, can provide efficient, standardized image processing scheme for zebra fish brain vascular development mechanism and brain vascular disease model research, and has wide application prospect.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

A prediction system includes: a terminal; and a processor, communicatively coupled to the processor. The processor is configured to: acquire medical treatment information including images captured at at least one of before, during, immediately after, and after a predetermined period from treatment of a patient with a symptom of a vascular disease; classify a condition of the patient based on a classification image; learn the medical treatment information in association with the condition of the patient; and predict at least one of a treatment effect and a prognosis when treatment intervention is performed for the patient based on a learning result.

Systems and methods are disclosed for evaluating a patient with vascular disease. One method includes receiving patient-specific data regarding a geometry of the patient's vasculature; creating an anatomic model representing at least a portion of a location of disease in the patient's vasculature based on the received patient-specific data; identifying one or more changes in geometry of the anatomic model based on a modeled progression or regression of disease at the location; calculating one or more values of a blood flow characteristic within the patient's vasculature using a computational model based on the identified one or more changes in geometry of the anatomic model; and generating an electronic graphical display of a relationship between the one or more values of the calculated blood flow characteristic and the identified one or more changes in geometry of the anatomic model.

The present invention provides methods for treating vascular diseases with hemogenic endothelial cells (HEs) obtained in vitro from pluripotent stem cells. The present invention also provides compositions and methods of producing the HEs.

Quinazoline dione compounds are provided for treating cardiac indications such as hypertrophic cardiomyopathy and diastolic dysfunction. Diseases treated by the methods described herein include, but are not limited to, cardiomyopathy, hypertrophic cardiomyopathy (HCM), abnormal heart rhythms, aortic disease, Marfan syndrome, coronary artery disease, heart attack, heart failure, rheumatic heart disease, peripheral vascular disease, stroke, deep vein thrombosis, and pulmonary embolism.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from aspirin, atorvastatin, valsartan, hydrochlorothiazide, folic acid substances and pharmaceutically acceptable auxiliary materials. The pharmaceutical composition provided by the invention has the advantages that the pharmaceutical composition provided by the invention has a multi-target synergistic prevention effect on vascular diseases, especially cerebral embolism, that is, the composition not only can reduce blood pressure, blood fat and blood homocysteine level, but also has an effect of preventing thrombosis, and reduces the risk of cerebral apoplexy. In addition, the form of the pharmaceutical composition is beneficial to improving the medication compliance of patients.

The invention belongs to the field of pathologies affecting the central nervous system: in particular, severe cerebral pathologies, more particularly those restricted by the presence of the blood-brain barrier (BBB): gliomas, cerebral metastases, neurodegenerative diseases (e.g. Alzheimer's, Parkinson's or ALS), genetic diseases (Huntington's, myopathies, Leigh syndrome, Rett syndrome), but also to the field of cancers, musculoskeletal and immunological disorders, vascular diseases (thrombus) in numerous organs (e.g. liver, kidney or muscle) and in combination with numerous therapeutic approaches (e.g. chemotherapy, immunotherapy, targeted therapy or gene therapy). The invention relates to a microbubble comprising a fluorinated polymer or copolymer and a fluorinated gas, to the use thereof and also to the polymer or copolymer intermediate compounds.

In an exemplary example, methods and systems are disclosed herein for treating vascular disease by implanting a stent within a vessel and using intravascular imaging to determine and ensure that the stent is properly implanted and produces the desired and effective results. For example, a system can obtain optical shape sensing data and intravascular imaging data of a vessel. The system can process the optical shape sensing data and the intravascular imaging data to generate three-dimensional models and images of the vessel immediately before and after the stent is implanted in the vessel and make an exact comparison of the before and after images to ensure that the stent is properly implanted and will produce or is producing the desired and effective results. The exact comparison can be based on a derived diameter associated with the location of the stent placement in the vessel, which is based on the generated pre- and post- three-dimensional models.

The present invention relates to a device for intravascular drug delivery, preferably an implant for intravascular drug delivery. The invention also relates to a device for a method for preventing or treating neurological diseases, neoplastic diseases, cardiac diseases, vascular diseases, immune diseases, carcinoids, infectious diseases and / or edema.

Provided herein is an intravascular endoscope with an improved balloon design. The endoscope comprises an anterior balloon with a camera, light source, and working channel port for visualization and therapeutic access. One or more posterior balloons are positioned inferior to, at the same level as, or superior to the anterior balloon. Inflation of the one or more posterior balloons pushes the anterior balloon against the blood vessel wall while maintaining a channel for blood flow past the anterior balloon. The endoscope enables real-time, direct visualization of the interior of blood vessels for diagnosis and treatment of vascular diseases while preserving critical blood flow. Additional imaging modalities, such as ultraviolet and infrared, can be incorporated to enhance tissue characterization. Visual markers on devices inserted through the working channel improve visibility and guidance under endoscopic imaging. The endoscope is compatible with arteries and veins throughout the body and provides advantages over traditional imaging techniques for managing vascular disease.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The present application relates to the technical field of medical diagnosis, and discloses a blood oxygen real-time monitoring system based on a photoelectric volume pulse wave, which comprises the following steps: inducing a vasomotor response through periodic thermal excitation, and demodulating a physiological pulse wave from a thermal modulation signal by using a synchronous phase-locked amplification technology. The present application solves the signal acquisition problem in a silent low perfusion state, converts background signals regarded as invalid noise in traditional monitoring into a resolvable vital sign carrier, and realizes non-invasive evaluation of microcirculation function through a thermal response index, thereby providing an early screening means for peripheral vascular diseases. The system maintains medical-grade precision while realizing the engineering feasibility of a consumer-grade device with an extremely simple hardware architecture.

The present disclosure is directed to compositions comprising between 50% and 95% weight per weight (w / w) of acetic acid, between 0.1% and 5% (w / w) of butyric acid or a derivative thereof, and between 0.1% and 5% (w / w) of Quercetin or a derivative thereof. Further, methods of use such as for the treatment and prevention of a medical condition associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, high blood pressure, vascular diseases, viral infection, and any combination thereof, in a subject in need thereof are also provided.

The present disclosure relates to engineered phospholipid or lysophospholipid (e.g., sphingosine 1-phosphate (S1P)) chaperones derived from apolipoprotein M (ApoM)-Fc fusion proteins with extended half-life in vivo. The disclosed ApoM-Fc fusion proteins provide a safe, highly efficient and effective way of delivering S1P to endothelial cells and all tissues of the body.

The application discloses a portable detection kit for assisting in predicting a cerebral vascular risk, a blood sample is processed through a sample processing module and input corresponding test paper, a detection result of the test paper is collected by a biological sensing module, and the detection result is calibrated and temporarily stored through an electronic control module, so that a user can acquire the calibrated detection result through a target device in an NFC touch mode and automatically send the calibrated detection result to a cerebral vascular disease monitoring digital platform, cerebral vascular risk prediction is performed by the cerebral vascular disease monitoring digital platform, and the portable detection kit has the beneficial effects of high portability, simple operation and high detection result accuracy.

This invention relates to compositions containing acetic acid, butyric acid, and quercetin, and to the use thereof. This disclosure relates to a composition comprising, by weight, 50% to 95% (w / w) acetic acid, 0.1% to 5% (w / w) butyric acid or its derivatives, and 0.1% to 5% (w / w) quercetin or its derivatives. Furthermore, methods for use in the treatment and prevention of medical conditions associated with cancer, inflammatory diseases or disorders, metabolic disorders, obesity, diabetes, hypertension, vascular diseases, viral infections, and any combination thereof, and for use in subjects in need thereof.

This invention discloses an intestinal fungus Saccharomyces cerevisiae M7015 and its applications belong to the field of microbial technology. Saccharomyces cerevisiae The accession number for M7015 is GDMCC No. 66195. This invention first demonstrated, using a mouse subcutaneous stroma embolism model, that the aforementioned strain can promote angiogenesis; secondly, using mouse and Bama miniature pig myocardial infarction models, it was found that the aforementioned strain can promote collateral angiogenesis in ischemic areas of the heart and improve cardiac function. This invention not only fully elucidates... Saccharomyces cerevisiae M7015 promotes the formation of collateral vessels in the heart and improves cardiac function, and also reveals the broad application prospects of this bacterium in the treatment of vascular diseases.

The present disclosure provides compounds capable of exhibiting effects similar to those of 2-Cys-peroxyredoxin (2-Cys-Prx) in the body with excellent pharmacological effects and reduced side effects such as reduced cytotoxicity, and pharmaceutical uses thereof. The compounds of the present disclosure and their pharmaceutically acceptable salts are useful for the treatment or prevention of vascular diseases, particularly ischemic coronary artery disease, arteriosclerosis, vascular restenosis, or pulmonary arterial hypertension. The compounds of the present invention and their pharmaceutically acceptable salts are particularly useful for the treatment or prevention of pulmonary arterial hypertension. The invention also provides methods of preparing the compounds of the present disclosure.

The invention relates to the technical field of cerebrovascular disease thrombectomy, and discloses an auxiliary device for cerebrovascular disease thrombectomy, which comprises two sliding joint mechanisms and a catheter limiting mechanism. According to the auxiliary device for the thrombectomy operation of the cerebrovascular disease, by means of the relative mobility of the X axis, the Y axis and the Z axis, the catheter positioning capacity at any space position can be achieved, the application range of the device is widened, the shaft body design is adopted, the occupation degree of the operation space can be reduced, and in addition, due to the fact that the auxiliary device is placed on the ground and has the braking capacity at the joints, the operation efficiency is improved. And the working stability is relatively high.

Methods of treating diseases and disorders treatable by AMPK activation with sephin1 and related compounds, for example metabolic syndrome, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis (NASH), obesity, type 2 diabetes, insulin resistance, glucose intolerance, chronic pain, sarcopenia, a neuromuscular disorder, heart failure, cardiac hypertrophy, diabetic cardiomyopathy, cardiac reperfusion injury, chronic kidney disease, polycystic kidney disease, diabetic nephropathy, cardiovascular diseases, inflammatory bowel disease, arthritis, hypertension, peripheral vascular disease, nephrogenic diabetes insipidus, glaucoma, an eye disease or disorder, ocular neovascularization, β-hemoglobinopathy, cancer, fibrosis, cancer cachexia, and mitochondrial disease.